Oral Minoxidil Safety in Von Willebrand Disease
Bleeding Risk Assessment
Aspirin should be used with extreme caution or avoided in VWD patients with acquired von Willebrand syndrome (AvWS) who have increased bleeding risk 1
In patients with extreme thrombocytosis (platelet count >1 million/μL), AvWS must be ruled out with ristocetin cofactor and multimer analysis before starting any medication that could affect hemostasis 2
If extreme thrombocytosis persists and is accompanied by AvWS or bleeding events, aspirin and other antiplatelet agents should be avoided 2
Patients with VWD type 1 who have mild bleeding history and normal VWF activity levels (>50 IU/dL) can generally tolerate medications with cardiovascular effects 3
Laboratory Testing and Monitoring
Never assume VWD type without recent laboratory confirmation, as bleeding phenotype can change over time, particularly with development of AvWS 6, 1
Do not combine oral minoxidil with antiplatelet therapy in patients with platelet counts >1 million/μL without first excluding AvWS 2
Cardiovascular monitoring alone is insufficient - hemostatic parameters require concurrent assessment 7, 3